Details for New Drug Application (NDA): 022545
✉ Email this page to a colleague
The generic ingredient in TEKAMLO is aliskiren hemifumarate; amlodipine besylate. There are four drug master file entries for this compound. Additional details are available on the aliskiren hemifumarate; amlodipine besylate profile page.
Summary for 022545
Tradename: | TEKAMLO |
Applicant: | Novartis |
Ingredient: | aliskiren hemifumarate; amlodipine besylate |
Patents: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 022545
Generic Entry Date for 022545*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 150MG BASE;EQ 5MG BASE | ||||
Approval Date: | Aug 26, 2010 | TE: | RLD: | No | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 21, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 150MG BASE;EQ 10MG BASE | ||||
Approval Date: | Aug 26, 2010 | TE: | RLD: | No | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 21, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE;EQ 5MG BASE | ||||
Approval Date: | Aug 26, 2010 | TE: | RLD: | No | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 21, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 022545
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | TEKAMLO | aliskiren hemifumarate; amlodipine besylate | TABLET;ORAL | 022545-001 | Aug 26, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | TEKAMLO | aliskiren hemifumarate; amlodipine besylate | TABLET;ORAL | 022545-004 | Aug 26, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | TEKAMLO | aliskiren hemifumarate; amlodipine besylate | TABLET;ORAL | 022545-003 | Aug 26, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | TEKAMLO | aliskiren hemifumarate; amlodipine besylate | TABLET;ORAL | 022545-002 | Aug 26, 2010 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription